HOOSIER BEACON: The legacy of Alec Clowes
Upon his arrival in Indianapolis, Clowes began aggressively pursuing research that might lead to mass-produced pharmaceuticals.
Pharmaceutical
Articles
Medicare plan on payment for cancer drugs stirs battle
A Medicare proposal to test new ways of paying for chemotherapy and other drugs given in a doctor's office has sparked a furious battle, and cancer doctors are demanding that the Obama administration scrap the experiment.
Insulin’s surging price turns diabetes staple into luxury good
The three drugmakers that dominate the world diabetes market—Eli Lilly and Co., Novo Nordisk A/S and Sanofi—are introducing improved forms of insulin, with a price tag to match.
Allergan, Pfizer call off proposed record $160B merger
The biggest U.S.-based drugmaker, Pfizer Inc., will stay put thanks to aggressive new Treasury Department rules that succeeded in blocking Pfizer from acquiring rival Allergan and moving to Ireland—on paper—to reduce its tax bill.
Meth law opens door for fledgling drugmaker
A small manufacturer angling to pick up more business in Indiana makes cold and allergy medicine resistant to being abused by methamphetamine makers.
Lilly angles for arthritis blockbuster
Within six months, Eli Lilly and Co. could know whether the Food and Drug Administration has approved its latest drug, baricitinib, a once-a-day tablet for treating rheumatoid arthritis.
Lilly wins FDA approval for plaque psoriasis drug
For Eli Lilly and Co., the approval rewards a decade-long effort to re-enter the biotech and autoimmune spaces that it helped pioneer in the 1980s but then abandoned in the 1990s.
Express Scripts leader wants Anthem to stay client despite $15B suit
Express Scripts Holding Co.’s incoming CEO is trying to keep its biggest customer after Anthem Inc. sued to recoup billions of dollars in what it called excess payments for drugs and threatened to end their relationship.
Pence signs anti-methamphetamine proposals into law
Pharmacists in Indiana will be able to limit how much cold medicine customers can buy under a measure Indiana Gov. Mike Pence signed into law Monday.
Anthem slaps lawsuit on Express Scripts over drug pricing
The insurer’s CEO said in January that Anthem should be reaping an addition $3 billion per year in savings on drugs from Express Scripts, which manages its pharmacy benefits.
Indiana House passes two bills to curb meth
Two measures aimed at to reducing methamphetamine production in Indiana are on their way to the governor's desk after receiving approval from the full House.
For Lilly’s Cialis, glory days are over
The erectile-dysfunction drug, made famous by a slew of quirky commercials, is facing performance issues of its own.
Teva closing in on $40B buy of Allergan generics unit
Teva’s acquisition will make it the world’s largest maker of generic medicines, giving it greater negotiating power with governments and private-health insurers.
Lawmakers zeroing in on anti-meth plan
Bills would let pharmacists require prescriptions for suspicious customers trying to buy cold medicines with pseudoephedrine. But some drug store chains fear putting their pharmacists in danger.
Kroger to offer anti-overdose drug without prescription
The supermarket chain will make naloxone available in its pharmacies across Ohio and northern Kentucky, a region hard-hit by deadly heroin.
Proposal for cold medicine prescriptions being scaled back
The new version of the Indiana bill would classify pseudoephedrine in a way that most consumers would be able to buy it, but pharmacists could require a prescription from suspicious customers.
UPDATE: Pharmacist consultation bill clears senate committee
Indiana pharmacists could get the legal right to refuse to sell a common cold medicine used to make methamphetamine to suspicious customers under a bill a Senate committee approved Tuesday.
Lilly’s 2016 sales, profit guidance falls short of predictions
Indianapolis-based Eli Lilly and Co., which has promised to return to growth after a half-decade of falling revenue, indicated that 2016 earnings might be below analysts’ estimates.
First-of-a-kind drug approvals continued rise in 2015
The rising figures reflect an industry-wide focus on drugs for rare and hard-to-treat diseases, which often come with streamlined reviews, extra patent protections and higher price tags.
Deal puts IU doctor’s research on path to market
A professor in the Indiana School of Medicine is hopeful that an antibiotic cocktail he invented will one day improve the lives of millions of people, thanks in part to the Indiana University Research and Technology Corp., formed in 1997 to make work done by IU faculty and researchers available for commercial development.